Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

Craig-Hallum analyst Christian Schwab maintained a Buy rating on Formfactor (FORM – Research Report) today. The company’s shares closed yesterday at $39.60. Leverage the power of TipRanks ...

Semiconductor testing company FormFactor (NASDAQ:FORM) will be reporting results tomorrow after the bell. Here’s what to look for. FormFactor beat analysts’ revenue expectations by 3.8% last ...

Zooey Liao/CNET; Mykola Sosiukin/EyeEm via Getty It's tax season, and if you've received an unfamiliar income form this year, it might be a 1099 tax form. A 1099 form is used to document income ...

As such, qCLUE marries decades of development with the quadratic speedup provided by quantum computers. We numerically test qCLUE in several scenarios, demonstrating its effectiveness and proving it ...